Brought to you by 
Invitae closes $120mm Series F round
29 Jan 2015
Executive Summary
Not even a year after a $40mm Series E round, molecular diagnostics company Invitae Corp. tripled that fundraising to bring in $120mm in Series F money. New investors the Broe Group, Decheng Capital, Deerfield Management, OrbiMed, Perceptive Advisors, Rock Springs Capital, and Wellington Management Co. joined returning backers Casdin Capital, Genesys Capital, Genomic Health (a fellow IVD company focused on cancer testing from which Invitae was spun out of in 2012), Randy Scott (Genomic Health’s former CEO), Redmile Group, and Thomas McNerney & Partners. JP Morgan Securities was the placement agent.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Invitae closes $120mm Series F round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice